STOCK TITAN

Corcept Therapeutics Inc - CORT STOCK NEWS

Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a leader in developing cortisol-modulating therapies for metabolic, oncologic, and neuropsychiatric disorders. This page serves as the definitive source for verified news and regulatory updates about the company.

Access real-time press releases, clinical trial developments, and financial disclosures essential for tracking CORT's progress in pharmaceutical innovation. Our curated collection includes updates on GR antagonist research, FDA communications, and partnership announcements.

Key content categories include quarterly earnings reports, drug approval milestones, scientific conference presentations, and strategic collaborations. Investors will find timely information about Korlym® commercialization and pipeline advancements across 300+ proprietary compounds.

Bookmark this page for direct access to Corcept's official communications. Check regularly for updates on hypercortisolism treatments, oncology trials, and novel therapeutic applications of glucocorticoid receptor science.

Rhea-AI Summary

Corcept Therapeutics Incorporated has completed enrollment in the Phase 4 CATALYST trial, the largest study ever conducted to establish the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Approximately 25% of the over 1,000 patients enrolled were identified as having hypercortisolism, a higher rate than previously assumed. Final prevalence data will be shared at the American Diabetes Association’s 84th Scientific Sessions in June, with treatment data expected by year-end. The findings from CATALYST aim to improve the identification and treatment of patients with hypercortisolism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Summary
Corcept Therapeutics (NASDAQ: CORT) will unveil its first quarter financial results and share a corporate update on May 1, 2024. A conference call is scheduled for 5:00 p.m. Eastern Time. Participants need to register in advance to receive the dial-in number and access PIN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
-
Rhea-AI Summary
Corcept Therapeutics announces positive results from the open-label portion of the pivotal Phase 3 GRACE trial for relacorilant in patients with Cushing’s syndrome. The trial showed significant improvements in hypertension, hyperglycemia, and other key endpoints without adverse effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
Rhea-AI Summary
Corcept Therapeutics Incorporated completes enrollment in Phase 2 DAZALS trial for ALS patients, testing dazucorilant's efficacy in improving motor performance and quality of life. The study enrolled 249 patients and is expected to provide data by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in ROSELLA Phase 3 trial for ovarian cancer treatment with relacorilant and nab-paclitaxel, aiming to improve patient outcomes. The trial mirrors positive Phase 2 results, showing potential for relacorilant to enhance survival rates. Progression-free survival data expected by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in Phase 3 trial for relacorilant in patients with Cushing’s syndrome, targeting serious cardiometabolic comorbidities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) reported strong financial results for Q4 2023 and full year 2023, with revenue increases of 31% and 20% respectively. They reiterated revenue guidance for 2024 at $600 - $630 million. The company's net income also showed significant growth. Clinical development programs are progressing well, with key milestones expected this year. Corcept is on-track to submit an NDA for relacorilant in Cushing’s syndrome and report data from various trials in Cushing’s syndrome, ovarian cancer, ALS, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
-
Rhea-AI Summary
Corcept Therapeutics (CORT) announces preliminary results from the prevalence phase of its CATALYST study on Cushing’s syndrome in patients with difficult-to-control type 2 diabetes. The study, with 1,000 patients, reveals a 24% prevalence rate of hypercortisolism, higher than previously assumed. Final results to be presented at the American Diabetes Association’s 84th Scientific Sessions in June.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) will report Q4 and full-year 2023 financial results and provide a corporate update on February 15, 2024. A conference call is scheduled at 5:00 p.m. Eastern Time. Participants must register in advance to receive dial-in number and access PIN. A listen-only webcast and call replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) has appointed Roberto Vieira as President, Oncology. Vieira brings extensive experience in global commercialization of cancer medicines and building high-performing teams. He aims to lead Corcept's oncology division, initially focusing on ovarian cancer and expanding to other tumors, with a commitment to revolutionize cancer treatment through cortisol modulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
management
Corcept Therapeutics Inc

Nasdaq:CORT

CORT Rankings

CORT Stock Data

7.52B
93.36M
11.44%
81.8%
15.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY